Acetaminophen (or equivalent) + Dexamethasone (or equivalent) + Histamine H1 Receptor Antagonist + Histamine H2 Receptor Antagonist + MK-2010 + Steroid mouthwash (dexamethasone or equivalent) + Sacituzumab tirumotecan + Epinephrine for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Aug 2026: Trial registered, NCT07785609
  2. 7 Oct 2026: Trial started, NCT07785609

The trials

NCT07785609: A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

State
Under way
Phase
Phase 2
People
200 planned
Started
7 Oct 2026
Primary completion
30 Sep 2031
Arms
Part 1: Safety Lead-In Cohort, Part 2: Signal-Finding Cohorts
Results
None posted
  1. 25 Aug 2026: Trial registered
  2. 7 Oct 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.